bluebird bio, Inc. (LON:0HOH)
3.900
0.00 (0.00%)
At close: Mar 10, 2025
bluebird bio Revenue
bluebird bio had revenue of $38.71M USD in the quarter ending March 31, 2025, with 108.43% growth. This brings the company's revenue in the last twelve months to $103.95M, up 127.51% year-over-year. In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth.
Revenue (ttm)
$103.95M
Revenue Growth
+127.51%
P/S Ratio
0.45
Revenue / Employee
$419.14K
Employees
248
Market Cap
36.20M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
bluebird bio News
- 7 days ago - Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - Business Wire
- 9 days ago - Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity - Benzinga
- 9 days ago - Bluebird bio soars on amended deal with Carlyle, SK Capital - Seeking Alpha
- 9 days ago - Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
- 9 days ago - Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - Business Wire
- 14 days ago - Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
- 18 days ago - Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - Seeking Alpha
- 18 days ago - Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - Business Wire